Increased in vitro cellular drug resistance is related to poor outcome in high‐risk childhood acute lymphoblastic leukaemia
Authors:
- Britt‐Marie FrostBFBritt‐Marie Frost
- On Behalf Of The Nordic Society For Paediatric Haematology And OncologyOOOn Behalf Of The Nordic Society For Paediatric Haematology And Oncology
Open Access
- 23 July 2003
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 122 (3) , 376-385
Abstract
Summary. We determined the in vitro cellular drug resistance in 370 children with newly diagnosed acute lymphoblastic leukaemia (ALL). The resistance to each of 10 drugs was measured by the fluorometric microculture cytotoxicity assay (FMCA) and was related to clinical outcome. The median follow‐up time was 41 months. Risk‐group stratified analyses indicated that in vitro resistance to dexamethasone, doxorubicin and amsacrine were each significantly related to the probability of disease‐free survival. In the high‐risk (HR) group, increased in vitro resistance to dexamethasone (P = 0·014), etoposide (P = 0·025) and doxorubicin (P = 0·05) was associated with a worse clinical outcome. Combining the results for these drugs provided a drug resistance score with an independent prognostic significance superior to that of any other factor studied, with a relative risk of relapse in the most resistant group 9·8 times that in the most sensitive group (P = 0·007). The results in the intermediate‐risk (IR) and standard‐risk (SR) groups were less clear cut. In conclusion, our data indicate that in vitro testing of cellular drug resistance can be used to predict the clinical outcome in HR ALL, while the final evaluation of the results in IR and SR patients must await longer follow‐up.Keywords
This publication has 23 references indexed in Scilit:
- Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistanceLeukemia, 2001
- Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiationLeukemia, 2000
- Long-term results of large prospective trials in childhood acute lymphoblastic leukemiaLeukemia, 2000
- Prognostic impact of karyotypic findings in childhood acute lymphoblastic leukaemia: a Nordic series comparing two treatment periodsBritish Journal of Haematology, 2000
- Intensified treatment of acute childhood lymphoblastic leukaemia has improved prognosis, especially in non‐high‐risk patients: the Nordic experience of 2648 patients diagnosed between 1981 and 1996Acta Paediatrica, 1998
- Cell birth and death in childhood acute lymphoblastic leukaemia: how fast does the neoplastic cell clone expand?British Journal of Haematology, 1997
- Detection of tumor‐specific cytotoxic drug activity IN VITRO using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patientsInternational Journal of Cancer, 1994
- Clinical relevance of in vitro drug resistance testing in childhood acute lymphoblastic leukemia: The state of the artMedical and Pediatric Oncology, 1994
- Laboratory prediction of clinical chemotherapeutic drug resistance: a working model exemplified by acute leukaemiaEuropean Journal of Cancer, 1993
- Primary Bioassay of Human Tumor Stem CellsScience, 1977